Real World Data on CAR T-Cell Recipients: Are We There Yet?
Drs. Marcelo Pasquini and Miguel-Angel Perales discuss the history and significance of the Center for International Blood and Marrow Transplant Research (CIBMTR), a decades
A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older Patients
Dr. DeZern discusses two studies that show improved outcomes for older patients with AML using a venetoclax and hypomethylating agents combination.
A concise review of a topic that illustrates the relationship of basic research to clinical hematology
Dr. David Sallman reviews studies that show the profound negative connotation of TP53 mutation in myelodysplastic syndromes and the immediate need for effective, biologically rational, targeted therapies.
Dr. Sheth discusses advances in therapies for β-thalassemia syndromes including optimization of gene therapy and the use of agents that leverage molecular targets.
Dr. Jenny Despotovic covers the expanded therapeutic repertoire currently emerging to treat immune thrombocytopenia (ITP) as understanding of ITP disease biology improves.
Dr. Jordan examines the emergence of targeted therapy for hemophagocytic lymphohistiocytosis, a striking inflammatory disorder familiar to hematologists.
Dr. Paneez Khoury provides an overview of the diagnosis and treatment of lymphocytic variant hypereosinophilic syndromes.
Dr. Schiffman and Dr. Maese discuss pediatric cancer susceptibility disorders and their relevance to hematology as highlighted in a 2016 American Association for Cancer Research workshop.
Dr. Abdel-Wahab provides an overview of histiocytoses or histiocytic neoplasms, some of the most challenging hematologic disorders to diagnose and categorize.
Drs. Sojitra, Arber, and George cover the 2017 joint guidelines from ASH and the College of American Pathologists on testing for the initial workup of acute leukemia.
Dr. Hoggatt discusses stem cell transplantation and looks at new, targeted conditioning approaches that have recently emerged, where the potential patient pool could be remarkably expanded with the advent of new gene therapy and editing strategies.
Dr. George and Dr. Czuchlewski cover the World Health Organization's 2016 updates to the classification of myeloid neoplasms.
January-February 2019Volume 16, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.